LBA35 Phase II study of PARP inhibitor talazoparib and PD-L1 inhibitor avelumab in patients (pts) with microsatellite stable (MSS) recurrent/persistent endometrial cancer

Autor:	Gini F. Fleming, Y. Oladapo, Ursula A. Matulonis, Alexi A. Wright, Allison Gockley, Christin Whalen, Mary K. Buss, Panagiotis A. Konstantinopoulos, Madeline Polak, Niya Xiong, Carolyn N. Krasner, Susan Schumer, S. M. Campos, Cesar M. Castro, Joyce F. Liu, Meghan Shea, Richard T. Penson, Stephen A. Cannistra, Sara Bouberhan, Nabihah Tayob
Rok vydání:	2020
Předmět:	business.industry Endometrial cancer Phases of clinical research Hematology medicine.disease Avelumab chemistry.chemical_compound Oncology chemistry Microsatellite Stable PARP inhibitor medicine Cancer research Talazoparib In patient PD-L1 inhibitor business medicine.drug
Zdroj:	Annals of Oncology. 31:S1165
ISSN:	0923-7534
DOI:	10.1016/j.annonc.2020.08.2265
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::17152331063c731fc628539513e9ca40 https://doi.org/10.1016/j.annonc.2020.08.2265 Zobrazit plný text záznamu